Edit
Portola Pharmaceuticals
https://www.portola.com/Last activity: 25.08.2020
Active - Reference to Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing innovative therapeutics for cardiovascular and autoimmune/inflammatory diseases. The company successfully completed an IPO in 2013.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $179M
Founded date: 2003
Investors 3
| Date | Name | Website |
| - | Prospect V... | prospectve... |
| - | Lightstone... | lightstone... |
| 25.08.2020 | Abingworth... | abingworth... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 22.11.2011 | - | $89M | - |
| 08.05.2007 | IPO | $70M | - |
| 18.10.2006 | - | $20M | - |
Mentions in press and media 10
| Date | Title | Description |
| 30.10.2013 | Which venture capital firm’s healthcare investment picks secured the most IPOs? | I won’t get into Aratana Therapeutics (Nasdaq: PETX) because the biopharmaceutical company develops treatments for animals. Acceleron Pharma: (Nasdaq: XLRN) raised $96.7 million after it priced at the high end of its share price range. The ... |
| 13.04.2013 | Portola rolls out $115M IPO plan as more biotech outfits go public | The list of biotechs going public grows longer. With public investors warming to biotech IPOs, Portola Pharmaceuticals has proposed a public debut with a relatively sizable maximum aggregate offering amount of $115 million. The South San Fr... |
| 22.11.2011 | Portola Pharmaceuticals Raises $89M | The financing round included existing investors who were joined by Temasek, an Asia investment company, and Eastern Capital Limited. Proceeds will be used primarily to advance betrixaban, a once-daily, oral Factor Xa inhibitor, through Ph... |
| 22.11.2011 | Portola Pharmaceuticals Raises $89M in Funding | Portola Pharmaceuticals, a South San Francisco, CA-based company that discovers and develops innovative therapeutics for cardiovascular and autoimmune/inflammatory diseases has raised $89m in financing. Backers included existing investors w... |
| 09.07.2008 | Cardio drug maker Portola Pharmaceuticals takes $60M extension | San Francisco-based drug company Portola Pharmaceuticals has taken a $60 million extension to its third round of funding to see it through Phase II trials for betrixaban, a drug intended to prevent blood clots. The company is also working o... |
| 24.07.2007 | Biotech venture funding takes a hit, but devices are hot | Venture-capital financing may be at a six-year high, but the picture in life sciences is a mixed one. After a blowout first quarter, second-quarter fundings in biotechnology actually dropped 19 percent, to $1.1 billion, compared to the same... |
| 09.05.2007 | Cardiovascular biotech Portola Pharmaceuticals raises $70M, eyes IPO | See David Hamilton’s story over at VentureBeat Life Sciences. VentureBeat VentureBeat's mission is to be a digital townsquare for technical decision makers to gain knowledge about transformative technology and transact. Our site delivers es... |
| 08.05.2007 | Cardiovascular biotech Portola Pharmaceuticals raises $70M, eyes IPO | Portola Pharmaceuticals, a South San Francisco, Calif., biotech aiming to develop treatments for blood clots and other heart-related problems, raised $70 million in a third round of financing dominated by late-stage and public-market invest... |
| 18.10.2006 | Portola Pharma gets $20M debt financing | Portola Pharmaceuticals, a South San Francisco biotech company developing cardiovascular and vascular disease therapies, has raised $20 million in debt financing from Hercules Technology Growth Capital. Portola is already backed by venture ... |
| - | Which venture capital firm’s healthcare investment picks secured the most IPOs? | Biotechnology and healthcare companies have been going public at a good clip this year, at a rate that overshadows the past few years. But initial public offerings are not what they used to be. Although they used to mark an exit for a compa... |